BeyondSpring Valuation

Is BYSI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BYSI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BYSI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BYSI's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BYSI?

Key metric: As BYSI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BYSI. This is calculated by dividing BYSI's market cap by their current revenue.
What is BYSI's PS Ratio?
PS Ratio	34.8x
Sales	US$1.88m
Market Cap	US$69.56m

BYSI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	33.5x
Enterprise Value/EBITDA	-3.8x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does BYSI's PS Ratio compare to its peers?

The above table shows the PS ratio for BYSI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.1x
CELU Celularity	1.3x	n/a	US$49.5m
SRNE.Q Sorrento Therapeutics	0.9x	n/a	US$60.4m
PLX Protalix BioTherapeutics	2.7x	57.7%	US$103.7m
CASI CASI Pharmaceuticals	3.5x	34.3%	US$88.5m
BYSI BeyondSpring	34.8x	n/a	US$69.6m

Price-To-Sales vs Peers: BYSI is expensive based on its Price-To-Sales Ratio (34.8x) compared to the peer average (2.1x).

Price to Sales Ratio vs Industry

How does BYSI's PS Ratio compare vs other companies in the US Biotechs Industry?

147 Companies	Price / Sales	Estimated Growth	Market Cap
AMGN Amgen	4.7x	2.4%	US$159.07b
GILD Gilead Sciences	3.9x	2.4%	US$114.79b
BIIB Biogen	2.4x	1.4%	US$24.03b
MRNA Moderna	2.8x	7.5%	US$15.30b

147 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: BYSI is expensive based on its Price-To-Sales Ratio (34.8x) compared to the US Biotechs industry average (11.5x).

Price to Sales Ratio vs Fair Ratio

What is BYSI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BYSI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	34.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BYSI's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

ANI Pharmaceuticals

US$1.2b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$58.91

0.9%

14.9%

Collegium Pharmaceutical

US$973.3m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.27

-12.8%

20.5%

IQVIA Holdings

US$38.4b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$202.94

-6.8%

-0.9%